Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06524375
PHASE2

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

Sponsor: Genentech, Inc.

View on ClinicalTrials.gov

Summary

The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.

Official title: Phase II, Open-label, Prospective Single-arm, Multi-center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-treatment Period

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

118

Start Date

2024-08-09

Completion Date

2030-01-31

Last Updated

2026-02-25

Healthy Volunteers

No

Interventions

DRUG

Venetoclax

Venetoclax tablets will be administered as per the schedule specified in the arm.

DRUG

cBTKi Monotherapy

Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.

Locations (20)

Highlands Oncology Group

Springdale, Arkansas, United States

Rocky Mountain Cancer Centers (Aurora) - USOR

Aurora, Colorado, United States

Cancer Specialists of North Florida

Jacksonville, Florida, United States

Fort Wayne Medical Oncology and Hematology, Inc

Fort Wayne, Indiana, United States

Mission Blood and Cancer - MercyOne Cancer Center

Des Moines, Iowa, United States

American Oncology Partners of Maryland, PA

Bethesda, Maryland, United States

Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center

Boston, Massachusetts, United States

Nebraska Cancer Specialists St Francis - Grand Island

Grand Island, Nebraska, United States

Nebraska Cancer Specialists

Omaha, Nebraska, United States

Astera Cancer Care East Brunswick

East Brunswick, New Jersey, United States

San Juan Oncology Associates, PC

Farmington, New Mexico, United States

Oncology Hematology Care Inc - Cincinnati - USOR

Cincinnati, Ohio, United States

Ohio State University

Columbus, Ohio, United States

Willamette Valley Cancer Institute and Research Center

Eugene, Oregon, United States

Asante Rogue Regional Medical Center

Medford, Oregon, United States

Tennessee Oncology, PLLC - Chattanooga

Chattanooga, Tennessee, United States

Tennessee Oncology - Midtown

Nashville, Tennessee, United States

MD Anderson Cancer Center

Houston, Texas, United States

Texas Oncology- Northeast Texas

Tyler, Texas, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States